Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/CCM.0000000000004926 | DOI Listing |
Transfus Clin Biol
January 2025
Établissement Français du Sang, Bretagne, Rennes.
Objectives: This study aimed to measure the psychometrics qualities of an extended model of the Theory of Planned Behavior (TPB) applied to plasma donation, and its relevance in the evaluation of interventions aiming at converting whole-blood donors (WBD) to plasma donation.
Methods: Two studies were conducted. The first (N= 433) compared the efficacy of two communication strategies (standard strategy centered on motivations to donate vs.
Cureus
October 2024
Internal Medicine, Mardan Medical Complex, Mardan, PAK.
Background: Guillain-Barre Syndrome (GBS) is a severe autoimmune neuropathy that has to be treated quickly and efficiently in emergency situations, when both cost and effectiveness are vital.
Objective: To compare the clinical outcomes and cost-effectiveness of plasmapheresis and intravenous immunoglobulin (IVIG) in managing acute GBS in emergency departments.
Methodology: A prospective observational study conducted from January to December 2023 evaluated the treatment of adults with acute GBS using IVIG or plasmapheresis.
New Microbes New Infect
December 2024
Meilahti Vaccine Research Center, MeVac, Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Background: Early in the COVID-19 pandemic, convalescent plasma (CP) emerged as a potentially effective treatment neutralising SARS-CoV-2. Early CP therapy with high neutralising antibody (NAb) titre may benefit COVID-19 outpatients and, in sufficient quantities even some hospitalised patients. This study details the process of setting up a CP bank, containing high- and low-titre CP for a clinical trial.
View Article and Find Full Text PDFExp Clin Transplant
October 2024
From the Urology and Nephrology Research Center, Shahidbeheshti of Medical Sciences, Tehran, Iran.
Clear guidelines for therapeutic apheresis in children after renal transplant do not exist. This article reviews the current experiences with therapeutic apheresis in pediatric transplant recipients. The ideal characteristics of removable substances should have all of the following criteria for an effective therapeutic apheresis: large molecular weight (>15 kDa), prolonged half-life, rapid elimination from the plasma, high intravascular distribution, and low turnover rate.
View Article and Find Full Text PDFPLoS One
October 2024
Department of Nephrology and Institute of Nephrology, Sichuan Clinical Research Centre for Kidney Diseases, School of Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!